Caris Life Sciences, INC Form 4 insider transactions

Peter M Castleman, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

T Danny Phillips, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

Lloyd Minor, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

Joseph E Gilliam, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

David Paul Fredrickson, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

Jeff L Vacirca, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

Laura I Johansen, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

Jon Halbert, a Director of Caris Life Sciences, Inc., received 13,192 shares of common stock on August 14, 2026.

Jon Halbert, a Director of Caris Life Sciences, Inc., purchased 68,000 shares of common stock on May 15, 2026 for $14.56 per share.

Director George Poste acquired 1,600 shares of Caris Life Sciences common stock as part of his 2026 board retainer compensation.

Director Jonathan Knowles acquired 1,600 shares of Caris Life Sciences, Inc. as part of his 2026 board retainer compensation.

J. Russel Denton, Senior Vice President at Caris Life Sciences, Inc., reported a transaction involving common stock, including shares withheld for tax payments.

Luke Thomas Power, Senior Vice President, Chief Financial Officer, and Chief Accounting Officer of Caris Life Sciences, Inc., reported a transaction involving the sale of 9,771 shares of common stock.

David Spetzler, President of Caris Life Sciences, Inc., reported a transaction involving the sale of 13,856 shares of common stock.

Brian J. Brille, Vice Chairman and Executive Vice President of Caris Life Sciences, Inc., reported a transaction involving the sale of common stock.

David D. Halbert, a Director and 10% Owner of Caris Life Sciences, Inc., reported a disposition of 40,712 common shares.

Jeff L. Vacirca, a Director at Caris Life Sciences, Inc., reported the acquisition of 31,050 shares of common stock on May 11, 2026.

Caris Life Sciences Director Lloyd Minor acquired 2,492 shares of common stock on February 26, 2026, as compensation for 2025 board retainer fees.

Caris Life Sciences Director Jeff L. Vacirca acquired 2,492 shares of common stock in lieu of cash compensation for board retainer fees.

A director at Caris Life Sciences, David Paul Fredrickson, acquired 2,492 shares of common stock as compensation for 2025 board retainer fees.

Caris Life Sciences Director Jon Halbert acquired additional common stock as part of his 2025 board retainer compensation.

Caris Life Sciences Director T Danny Phillips acquired 3,739 shares of common stock at $20.06, increasing his beneficial ownership to 119,868 shares.

Caris Life Sciences Director Peter M. Castleman acquired 5,509 shares of common stock as compensation for board retainer fees.

Caris Life Sciences Director Peter M. Castleman exercised 2,500 stock options, acquiring common stock at $18.60 per share.

Caris Life Sciences' CFO, Luke Thomas Power, exercised stock options and subsequently sold a significant number of common shares on December 11, 2025, under a pre-arranged 10b5-1 trading plan.

Brian J. Brille, a Director and Vice Chairman at Caris Life Sciences, reported gifting a total of 1,300 shares of common stock.

Caris Life Sciences' Senior VP, General Counsel, and Secretary, John Russel Denton, purchased 4,184 shares of common stock for $24.09 per share.

Caris Life Sciences President David Baxley Spetzler purchased 400 shares of common stock at $23.85 per share in a pre-planned transaction.

T Danny Phillips, a director at Caris Life Sciences, Inc., exercised 100,000 stock options at $2.44 per share, acquiring common stock.

Caris Life Sciences Director George Poste reported exercising stock options and selling shares for tax purposes, increasing his indirect holdings.